GLP-1 agonists like Wegovy and Zepbound have revolutionized weight-loss treatment for people with obesity, allowing them to lose more weight than through lifestyle changes alone. Medicare may soon cover these medications as part of the Treat and Reduce Obesity Act (TROA), offering comprehensive obesity care for millions of Americans. This legislation aims to address disparities in healthcare access and reduce the economic burden of obesity-related medical costs. Advocates recommend proactive health planning and engagement with patient advocacy groups to support the passage of TROA and advance obesity care for all.
. If the provided articles seems to be less than 200 characters or it is an intro of the author, then try to generate an articles using this title: Medicare and Obesity – HealthyWomen
